[go: up one dir, main page]

UY31699A1 - Suspensiones de acetonido de triamcinolona de baja viscosidad y elevada floculacion para inyeccion intravitrea - Google Patents

Suspensiones de acetonido de triamcinolona de baja viscosidad y elevada floculacion para inyeccion intravitrea

Info

Publication number
UY31699A1
UY31699A1 UY31699A UY31699A UY31699A1 UY 31699 A1 UY31699 A1 UY 31699A1 UY 31699 A UY31699 A UY 31699A UY 31699 A UY31699 A UY 31699A UY 31699 A1 UY31699 A1 UY 31699A1
Authority
UY
Uruguay
Prior art keywords
low viscosity
injection
triamcinolone acetonide
intravitrea
floculation
Prior art date
Application number
UY31699A
Other languages
English (en)
Inventor
Ruma Sarakar
Bhagwati Kabra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31699A1 publication Critical patent/UY31699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen composiciones de acetonido de triamcinolona en suspension. Las composiciones en suspension tienen una viscosidad relativamente baja y son de fácil extrucion mediante una aguja calibre 27 o 30; pero son de elevada floculacion y se vuelven a dispersar con facilidad. Las composiciones son particularmente adecuadas para administrar por inyeccion intravítrea.
UY31699A 2008-03-11 2009-03-10 Suspensiones de acetonido de triamcinolona de baja viscosidad y elevada floculacion para inyeccion intravitrea UY31699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11

Publications (1)

Publication Number Publication Date
UY31699A1 true UY31699A1 (es) 2009-05-29

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31699A UY31699A1 (es) 2008-03-11 2009-03-10 Suspensiones de acetonido de triamcinolona de baja viscosidad y elevada floculacion para inyeccion intravitrea

Country Status (21)

Country Link
US (3) US8128960B2 (es)
EP (1) EP2262506B1 (es)
JP (1) JP5581227B2 (es)
KR (1) KR101555293B1 (es)
CN (1) CN101959519B (es)
AR (1) AR070824A1 (es)
AU (1) AU2009223649B2 (es)
BR (1) BRPI0909630B8 (es)
CA (1) CA2717605C (es)
CL (1) CL2009000573A1 (es)
DK (1) DK2262506T3 (es)
ES (1) ES2471122T3 (es)
MX (1) MX2010009974A (es)
PL (1) PL2262506T3 (es)
PT (1) PT2262506E (es)
RU (1) RU2481842C2 (es)
SI (1) SI2262506T1 (es)
TW (1) TWI468165B (es)
UY (1) UY31699A1 (es)
WO (1) WO2009114521A1 (es)
ZA (1) ZA201005839B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
KR101555293B1 (ko) * 2008-03-11 2015-10-06 알콘 리서치, 리미티드 저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액
WO2010074961A1 (en) * 2008-12-22 2010-07-01 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
CN104758118B (zh) 2010-10-15 2018-04-06 科尼尔赛德生物医学公司 用于进入眼睛的装置
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EP4566672A3 (en) * 2012-11-08 2025-08-13 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
US9539139B2 (en) 2013-05-03 2017-01-10 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
JP2017524419A (ja) 2014-06-20 2017-08-31 クリアサイド バイオメディカル，インコーポレイテッド 薬剤送達のための挿入深さを制御するための可変径カニューレ及び方法
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
JP2019514581A (ja) 2016-05-02 2019-06-06 クリアサイド バイオメディカル，インコーポレイテッド 眼の薬物送達のためのシステムおよび方法
WO2018031913A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
US11701368B2 (en) 2018-01-10 2023-07-18 Eye Co Pty Ltd Unit dose pharmaceutical of a dry powder of one or more glucocorticoid or mineralocorticoid fludrocortisone acetate and/or triamcinolone acetonide comprised in a syringe
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
CA3136814A1 (en) 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法
CN115969784B (zh) * 2022-12-26 2025-10-21 昆明积大制药股份有限公司 曲安奈德注射液的制备方法
WO2025114562A1 (en) * 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Intravitreal spironolactone suspension

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
AU4472396A (en) 1994-12-30 1996-07-24 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
NZ509797A (en) 1998-07-10 2003-11-28 Univ Sydney Prophylactic treatments of neovascularisation in macular degeneration using a steroid
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
WO2002015878A1 (fr) * 2000-08-25 2002-02-28 Senju Pharmaceutical Co., Ltd. Preparations en suspension aqueuse
PL368045A1 (en) * 2001-07-09 2005-03-21 Combinatorx, Incorporated Combinations for the treatment of inflammatory disorders
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
JP2006518382A (ja) 2003-02-20 2006-08-10 アルコン，インコーポレイテッド 眼の障害に罹患している人を処置するためのステロイドの使用
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
EP1663144A1 (en) * 2003-09-23 2006-06-07 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
KR20060123493A (ko) * 2003-12-23 2006-12-01 알자 코포레이션 제어된 전달을 위한 약물 조성물의 용해도를 증가시키는방법 및 제형
BRPI0506983A (pt) 2004-01-20 2007-07-03 Allergan Inc composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
JP4729482B2 (ja) 2004-05-31 2011-07-20 千寿製薬株式会社 透明組織可視化剤
US20060089590A1 (en) 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
AU2005306309A1 (en) 2004-11-17 2006-05-26 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Steroid formulation and methods of treatment using same
WO2006088134A1 (ja) * 2005-02-18 2006-08-24 Santen Pharmaceutical Co., Ltd. ステロイド化合物の副作用軽減または回避方法
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
KR101555293B1 (ko) * 2008-03-11 2015-10-06 알콘 리서치, 리미티드 저점도이면서 고도 응집된 유리체내 주사용 트리암시놀론 아세토니드 현탁액

Also Published As

Publication number Publication date
AU2009223649A1 (en) 2009-09-17
EP2262506B1 (en) 2014-05-07
AR070824A1 (es) 2010-05-05
PL2262506T3 (pl) 2014-09-30
JP2011513492A (ja) 2011-04-28
WO2009114521A1 (en) 2009-09-17
CA2717605C (en) 2012-05-15
DK2262506T3 (da) 2014-06-10
BRPI0909630B8 (pt) 2021-05-25
BRPI0909630B1 (pt) 2019-03-26
SI2262506T1 (sl) 2014-07-31
MX2010009974A (es) 2010-09-30
CN101959519A (zh) 2011-01-26
US8211880B2 (en) 2012-07-03
TW200940071A (en) 2009-10-01
KR101555293B1 (ko) 2015-10-06
PT2262506E (pt) 2014-06-24
RU2010141542A (ru) 2012-04-20
CA2717605A1 (en) 2009-09-17
US8128960B2 (en) 2012-03-06
US20120115829A1 (en) 2012-05-10
ES2471122T3 (es) 2014-06-25
BRPI0909630A2 (pt) 2015-09-22
ZA201005839B (en) 2011-10-26
HK1146464A1 (en) 2011-06-10
TWI468165B (zh) 2015-01-11
RU2481842C2 (ru) 2013-05-20
US20120116216A1 (en) 2012-05-10
EP2262506A1 (en) 2010-12-22
AU2009223649B2 (en) 2013-08-29
CL2009000573A1 (es) 2010-01-04
US20090233890A1 (en) 2009-09-17
JP5581227B2 (ja) 2014-08-27
CN101959519B (zh) 2013-03-20
KR20100127267A (ko) 2010-12-03

Similar Documents

Publication Publication Date Title
UY31699A1 (es) Suspensiones de acetonido de triamcinolona de baja viscosidad y elevada floculacion para inyeccion intravitrea
SV2008003071A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
ES2530170T3 (es) Material de filtro transparente
BR112012016021A8 (pt) Formulações estáveis para liofilização de partículas terapêuticas
UY31198A1 (es) Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones.
MX2022003458A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
ATE522593T1 (de) Textilpflegemittel mit formaldehydfängern
UY37098A (es) Moduladores de ror-gamma
UY28252A1 (es) Compuestos de benzopirano útiles para tratar estados inflamatorios
PA8854101A1 (es) Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
AR059330A1 (es) Composiciones acondicionadoras del cabello
EA201891754A1 (ru) Композиции гиалуроновой кислоты, включающие мепивакаин
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
AR060739A1 (es) Composiciones orales que comprenden polimeros de siloxano
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
PA8769401A1 (es) Hormigon con alta funcionalidad mediante control de proporciòn de material fino-a- granular
BR112012024131A2 (pt) Emulsões úteis em bebidas.
GT200600475A (es) Derivados de pirazina
BR112014032801A2 (pt) composições líquidas de racecadotril
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
AR101911A1 (es) Composiciones de polietileno con propiedades ópticas mejoradas
CL2022003194A1 (es) Composiciones farmacéuticas inyectables y usos de las mismas
UY28247A1 (es) Compuestos de benzopirano para uso en el tratamiento y la prevención de afecciones relacionadas con la inflamación.
MX2010003914A (es) Nuevas composiciones a base de taxoides.
BR112016022628A2 (pt) Composição, processo para produzir um copolímero em bloco, e, copolímero em bloco

Legal Events

Date Code Title Description
105 Application deemed to be withdrawn (no grant fee paid)

Effective date: 20201218